Collectively, our study is the first to delineate how IDO1, when expressed by cancer cells, modulates glycolysis, filling a previously unexplored gap regarding IDO1's distinct impact on glucose metabolism across different cell types and pathological states, especially within the intricate tumor microenvironment. This evidence concerns the gene IDO1 and cancer.